Legal Settlements and Loss Contingencies	6 Months Ended
Jun. 30, 2023
Legal Settlements and Loss Contingencies	NOTE 9 – Legal settlements and loss contingencies: In the second quarter of 2023, Teva recorded expenses of $462 million in legal settlements and loss contingencies, compared to $729 million in the second quarter of 2022. Expenses in the second quarter of 2023 were mainly related to a provision in connection with the U.S. DOJ criminal antitrust charges on the marketing and pricing of certain Teva USA generic products, an update to the estimated settlement provision related to some of the remaining opioid cases including an agreement in principle on private hospital cases, and an update to the provision related to the settlement in the reverse-payment antitrust litigation over certain HIV medicines. Expenses in the second quarter of 2022 were mainly related to an update of the estimated settlement provision recorded in connection with the remaining opioid cases. See note 10. In the first six months of 2023, Teva recorded expenses of $695 million in legal settlements and loss contingencies, compared to $1,854 million in the first six months of 2022. Expenses in the first six months of 2023 were mainly related to an update to the estimated settlement provision related to the remaining opioid cases, the provision relating to the U.S. DOJ criminal antitrust charges on the marketing and pricing of certain Teva USA generic products, an update to the estimated provision related to the DOJ patient assistance program litigation and the provision related to the settlement of the reverse-payment antitrust litigation over certain HIV medicines. Expenses in the first six months of 2022 were mainly related to an update of the estimated settlement provision recorded in connection with the remaining opioid cases. As of June 30, 2023 and December 31, 2022, Teva’s provision for legal settlements and loss contingencies recorded under accrued expenses and other taxes and long-term liabilities was $4,704 million and $4,186 million, respectively.

Legal Settlements and Loss Contingencies

6 Months Ended

Jun. 30, 2023

Legal Settlements and Loss Contingencies

NOTE 9 – Legal settlements and loss contingencies:

In the second quarter of 2023, Teva recorded expenses of $462 million in legal settlements and loss contingencies, compared to $729 million in the second quarter of 2022. Expenses in the second quarter of 2023 were mainly related to

a provision in connection with

the U.S. DOJ criminal

antitrust charges on the marketing and pricing of certain Teva USA generic products, an update to the estimated settlement provision related to some of the remaining opioid cases including an agreement in principle on private hospital cases, and an update to the provision related to the settlement in the reverse-payment antitrust litigation over certain HIV medicines. Expenses in the second quarter of 2022 were mainly related to an update of the estimated settlement provision recorded in connection with the remaining opioid cases. See note 10.

In the first six months of 2023, Teva recorded

expenses

of $695 million in legal settlements and loss contingencies, compared to $1,854 million in the first six months of 2022.

Expenses

in the first six months of 2023

were

mainly related to an update to the estimated settlement provision related to the remaining opioid cases, the

provision relating to the

U.S. DOJ criminal antitrust charges on the marketing and pricing of certain Teva USA generic products, an update to the estimated provision

related to

the DOJ patient assistance program litigation and the provision related to the settlement of the reverse-payment antitrust litigation over certain HIV medicines.

Expenses

in the first six months of 2022

were

mainly related to an update of the estimated settlement provision recorded in connection with the remaining opioid cases.

As of June 30, 2023 and December 31, 2022, Teva’s provision for legal settlements and loss contingencies recorded under accrued expenses and other taxes and long-term liabilities was $4,704 million and $4,186 million, respectively.